Cargando…
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
Since the first clinical report in 2013, inhibitors of the intracellular kinase BTK (BTKi) have profoundly altered the treatment paradigm of B cell malignancies, replacing chemotherapy with targeted agents in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstr...
Autores principales: | Smith, C. I. Edvard, Burger, Jan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222783/ https://www.ncbi.nlm.nih.gov/pubmed/34177947 http://dx.doi.org/10.3389/fimmu.2021.689472 |
Ejemplares similares
-
Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF-κB Activation and MAPK Pathways
por: Campillo-Gimenez, Laure, et al.
Publicado: (2018) -
NFκB and Kidney Injury
por: Song, Ning, et al.
Publicado: (2019) -
BCAP Regulates Dendritic Cell Maturation Through the Dual-Regulation of NF-κB and PI3K/AKT Signaling During Infection
por: Miao, Yuhui, et al.
Publicado: (2020) -
Nuclear Factor κB (NF-κB)–Mediated Inflammation in Multiple Sclerosis
por: Zhou, Yifan, et al.
Publicado: (2020) -
Impaired B Cell Apoptosis Results in Autoimmunity That Is Alleviated by Ablation of Btk
por: Wright, Jacqueline A., et al.
Publicado: (2021)